This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

19 Jul 2011

Roche to Seek Approval for Breast Cancer Drug Pertuzumab

Roche plans to submit the study results of pertuzumab for global regulatory approval this year.

Swiss pharma giant Roche has announced that pertuzumab, a treatment for breast cancer, has reached its primary endpoint in a Phase III study.


Roche plans to seek approval for the drug, which works by inhibiting growth of cancer-causing protein HER2, in the US and Europe later this year.


The trial showed that pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy helped patients with breast cancer live longer, without the disease getting worse.


Roche said that it would provide more detailed data at an upcoming medical conference later this year, and added that no new safety signals were observed and adverse events were consistent with those seen in prev

Related News